Literature DB >> 24065197

CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.

M K Sibin1, Dhananjaya I Bhat, Ch Lavanya, M Jeru Manoj, S Aakershita, G K Chetan.   

Abstract

Over the years, deletions of CDKN2A (p16) tumor suppressor gene has been studied using FISH and multiplex PCR, with major focus on exon 2 in various cancers, and the frequency of mutation is found to be varied in different studies. In this study, we analyzed the deletion status of all three exons of p16 and frequency of exon 2 somatic point mutations in glioma from the Indian population and its clinical implications. Multiplex PCR was carried out in order to check deletion of all 3 exons in 50 glioma samples. Nonconventional PCR-SSCP analysis and sequencing was done to identify mutations in 48 cases. Deletion of at least one of the three exons of p16 INK4A was observed in ten cases (20 %). The frequencies of exon-wise deletions were 10 % for exon 1, 4 % for exon 2, and 8 % for exon 3. Two out of 48 samples were positive for mutations in p16 exon 2. One sample had a transition of G to C on position 147 with a codon change TGG to TGC which does not contribute to the protein structure. Another sample had a transversion of A to G on the position 154 with a codon change ATG to GTG with change in amino acid methionine to valine in 52nd position. Deletion pattern was found to be varied in three exons. Frequency of p16 gene mutation was less in the Indian population (4.2 %), and this mutation does not contribute to any remarkable change in protein structure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065197     DOI: 10.1007/s13277-013-1201-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR.

Authors:  A Perry; T Nobori; N Ru; K Anderl; T J Borell; G Mohapatra; B G Feuerstein; R B Jenkins; D A Carson
Journal:  J Neuropathol Exp Neurol       Date:  1997-09       Impact factor: 3.685

2.  Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients.

Authors:  S Mochizuki; Y Iwadate; H Namba; Y Yoshida; A Yamaura; S Sakiyama; M Tagawa
Journal:  Int J Oncol       Date:  1999-11       Impact factor: 5.650

Review 3.  Genetics of adult glioma.

Authors:  McKinsey L Goodenberger; Robert B Jenkins
Journal:  Cancer Genet       Date:  2012-12-11

4.  Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.

Authors:  T Tsuzuki; S Tsunoda; T Sakaki; N Konishi; Y Hiasa; M Nakamura
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

5.  PIK3CA alterations in primary (de novo) and secondary glioblastomas.

Authors:  Daisuke Kita; Yasuhiro Yonekawa; Michael Weller; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2007-01-18       Impact factor: 17.088

6.  Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.

Authors:  D G Walker; W Duan; E A Popovic; A H Kaye; F H Tomlinson; M Lavin
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

7.  Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.

Authors:  Y Ono; T Tamiya; T Ichikawa; K Kunishio; K Matsumoto; T Furuta; T Ohmoto; K Ueki; D N Louis
Journal:  J Neuropathol Exp Neurol       Date:  1996-10       Impact factor: 3.685

Review 8.  Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.

Authors:  P M Pollock; J V Pearson; N K Hayward
Journal:  Genes Chromosomes Cancer       Date:  1996-02       Impact factor: 5.006

9.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

10.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

View more
  2 in total

1.  p16 hypermethylation: a biomarker for increased esophageal cancer susceptibility in high incidence region of North East India.

Authors:  Mandakini Das; Bhaskar Jyoti Saikia; Santanu Kumar Sharma; Gaganpreet Singh Sekhon; Jagadish Mahanta; Rup Kumar Phukan
Journal:  Tumour Biol       Date:  2014-11-01

2.  CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.

Authors:  M K Sibin; Dhananjaya I Bhat; K V L Narasingarao; Ch Lavanya; G K Chetan
Journal:  Tumour Biol       Date:  2015-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.